Updated on 29 July 2026
Strategic partnerships for the clinical validation and market deployment of ELEarly Dementia
COO at ELE Biotech
Madrid, Spain
About
ELE Biotech is developing ELEarly Dementia, a blood-based platform that combines a proprietary biomarker with analytical interpretation software to identify and stratify the risk of dementia.
Designed as a first-line risk-stratification tool, ELEarly Dementia aims to support earlier patient prioritisation for further clinical evaluation. The technology is compatible with standard qPCR infrastructure already available in clinical laboratories.
We are seeking strategic partnerships with:
• Hospitals, memory clinics and clinical research groups for multicentre clinical validation and future implementation studies.
• Clinical laboratories, IVD companies and industrial partners for analytical validation, scale-up, manufacturing and regulatory development under IVDR.
• Distributors and market-access partners for future commercial deployment in Spain and international markets.
• Pharmaceutical and healthcare organisations interested in early patient stratification and more efficient diagnostic pathways.
We are open to discussing collaborative studies, pilot projects, co-development, industrialisation and future commercial partnerships.
Similar opportunities
Project cooperation
- Early
- Research
Juan Luis Chico García
CSO at MAUTILUS EHEALTH SL
Madrid, Spain
Product
Real-World Evidence Intelligence
- Distribution Partner
- Pharmaceutical industry
Maria Natividad Chichón García
CEO-Cofounder en Mential at Mential
Madrid, Spain
Service
Out-of-clinic population screening programmes for pharma, public health and insurers
- Others
- Digital health
- Health innovation
- Pharmaceutical industry
Sofía Bardají
Business Development at Ailin Health
Madrid, Spain